Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 111 Triple Negative Breast Neoplasms 25 Lung Neoplasms 8 Pancreatic Neoplasms 6 Neoplasm Metastasis 6 Colonic Neoplasms 6 Ovarian Neoplasms 5 Neoplasms 5 Melanoma 5 Colorectal Neoplasms 5 Stomach Neoplasms 4 Head and Neck Neoplasms 4 Esophageal Neoplasms 4 Sarcoma 3 Liver Neoplasms 3 Kidney Neoplasms 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Multiple Myeloma 2 Motor Activity 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Laryngeal Neoplasms 2 Gastrointestinal Neoplasms 2 Fatigue 2 Fallopian Tube Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Bile Duct Neoplasms 2

Interventions

Trastuzumab 3 pyrotinib 2 pertuzumab 2 Fulvestrant 2 tucatinib 1 palbociclib 1 disitamab vedotin 1 atezolizumab 1 RC48 antibody 1 Drug Therapy 1 Docetaxel 1 Capecitabine 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × Drug Therapy × Breast × Clear all

NCT05188495 2022-01-12

HELP

Peking University Cancer Hospital & Institute

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡